Moderna, Inc.

NASDAQ: MRNA
$324.21
-$7.67 (-2.3%)
Closing price October 15, 2021
Friday afternoon's analyst upgrades and downgrades included Chubb, Domino’s, Lam Research, Moderna, Riot Blockchain and more.
Vaccine maker Moderna has announced it is working on a new vaccine, and another COVID-19 treatment is getting hammered.
Here's a look at how August's most-discussed stocks on WallStreetBets performed in the month. Sometimes, talk is not cheap.
Friday’s top analyst upgrades and downgrades included BP, Cloudflare, Expedia, FireEye, Marathon Oil, Moderna, Pinduoduo, Vertex Pharmaceuticals and ViacomCBS.
COVID-19 vaccine maker Moderna, silver miner Hecla, and entertainment giant ViacomCBS are scheduled to report quarterly results before markets open Thursday morning.
Our earnings preview for Wednesday afternoon and Thursday morning includes a COVID-19 vaccine maker, a chipmaker and a company that designs and builds hydrogen fuel cells.
Here, 24/7 Wall St. has put together a preview of a few of the most anticipated quarterly reports due this week, including those from Airbnb, Best Buy, Home Depot, Moderna, Nvidia and Salesforce.
24/7 Wall St. has compiled a list of a few of the biggest movers along why they are moving, a recent trading history and what the consensus estimate is from analysts.
Monday's top analyst upgrades and downgrades included AMC Entertainment, Bed Bath & Beyond, Halliburton, Intuit, Moderna, Nikola, Phillips 66, Stitch Fix and Virgin Galactic.
The November 30 short interest data has been compared with the previous report, and short interest moves in these selected biotech stocks were mixed.
Wednesday's top analyst calls included American Express, Apple, Baidu, CarMax, Chewy, Lululemon Athletica, Micron Technology, Moderna, Slack, Walt Disney and Zoom Video Communications.
COVID-19 stocks were on the move on Wednesday after a few huge updates in regards to vaccine approval.
Moderna shares continued to run higher on Monday after the company announced an update for the primary efficacy analysis for its late-stage coronavirus vaccine trial.
The November 13 short interest data has been compared with the previous report, and short interest in most of these selected biotech stocks decreased.
Here is an update on the stocks of each major player in the COVID-19 arena, including brief trading histories and consensus price targets.